Last reviewed · How we verify
NCT05710159: iBLAD-app
The iBlad App - a National, Exploratory Study on a Multimodality Smartphone App for Bladder Cancer Patients
trial testing iBLAD Application to monitor symptoms and quality of life by the use of pateint-reported outcomes in Bladder Cancer in 100 participants. Status unknown.
30 June 2024
Quick facts
| Lead sponsor | Odense University Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 12 December 2022 |
| Primary completion | 30 June 2024 |
| Estimated completion | 30 December 2024 |
| Sites | 2 locations across Denmark |
Drugs / interventions tested
- iBLAD Application to monitor symptoms and quality of life by the use of pateint-reported outcomes
Conditions studied
- Bladder Cancer — all drugs for Bladder Cancer →
Sponsor
Odense University Hospital
Who can join
Adults 18 to 100, any sex, with Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aims of this project are: * to develop and implement a national multimodality application for patients with bladder cancer that builds upon knowledge from the iBLAD study. * to investigate how the app, containing PRO questions on symptoms and QoL, information for health care providers, and peer-to-peer advice, can provide more knowledge on symptoms, QoL, and the need for supportive care. * to examine the usability of and patient satisfaction with the app using qualitative methods.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05710159
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bladder Cancer
Currently open trials in the same condition.
- NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
- NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
- NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting
Other Odense University Hospital trials
Trials by the same sponsor.
- NCT07163091 — Bracing After Ankle Fracture · NA · not yet recruiting
- NCT07521696 — Physical Recovery During Bracing After Ankle Fracture (Re-BAF) · NA · not yet recruiting
- NCT07466212 — QoLIDia: Quality of Life in Cancer Patients With Diabetes During Immunotherapy · not yet recruiting
- NCT07191379 — Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma · Phase 4 · not yet recruiting
- NCT07170085 — Positioning of Children With Acute Respiratory Insufficiency · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05710159 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Odense University Hospital
- Last refreshed: 1 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05710159.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing